SCYNEXIS, Inc., a biotechnology company, offers therapies for the treatment of yeast infections in the United States. The company is headquartered in Jersey City, New Jersey.
| Revenue (TTM) | $20.60M |
| Gross Profit (TTM) | $20.60M |
| EBITDA | $-36.54M |
| Operating Margin | 56.40% |
| Return on Equity | -16.50% |
| Return on Assets | -13.40% |
| Revenue/Share (TTM) | $0.41 |
| Book Value | $1.13 |
| Price-to-Book | 0.80 |
| Price-to-Sales (TTM) | 2.16 |
| EV/Revenue | 0.0876 |
| EV/EBITDA | 0.05 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1809.00% |
| Shares Outstanding | $44.66M |
| Float | $37.98M |
| % Insiders | 3.49% |
| % Institutions | 27.89% |